Los puntos clave no están disponibles para este artículo en este momento.
Patients with NMOSD with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies.
Sato et al. (Sat,) studied this question.